The Rna Platform a Revolution in Therapeutics
Total Page:16
File Type:pdf, Size:1020Kb
THE RNA PLATFORM A REVOLUTION IN THERAPEUTICS Pharmaceutical Paul-Philippe Champagne, PhD, PEng Senior Process Engineer Divyang Patel CQV and Compliance Specialist The RNA platform is a revolution in therapeutics The recent coronavirus pandemic has revolutionized medical innovation. + The rapid growth in requirement for therapeutics, including vaccines, 30 has brought the RNA platform to the forefront. However, the relevant literature is focused either exclusively on the molecular biology of RNA or on the development of RNA products. As such, we provide you with YEARS an accessible introduction on this revolutionary technology that bridges OF EXPERIENCE IN THE the gap between the science and its application. We begin by giving you PHARMA an overview of RNA and how biopharmaceutical companies are using BIOTECH & this novel technology in a wealth of diverse pharmaceutical products. medical device We also discuss key processes for the development and manufacture of RNA therapies, with mRNA vaccines as a case study. Lastly, we MARKET highlight the potential of this technology and discuss facility delivery. Messenger ribonucleic acid (mRNA) is a naturally occurring A plethora of RNA products molecule in the cell. It is primarily used as an intermediate in the transfer of genetic information encoded in deoxyribonucleic acid Owing to the versatile nature of the RNA platform, it is being used (DNA) to produce proteins. DNA is frst transcribed into mRNA in to develop vaccines for infuenza, coronavirus, and other infectious the nucleus of the eukaryotic cell, and then the mRNA is translated diseases (Jackson et al., 2020; Pardi et al., 2018). mRNA vaccines into proteins in the cell’s cytoplasm. are also in progress for human cancers (Pardi et al., 2018). There are numerous other therapeutics in the pipeline that use some mRNA technology allows for the safe delivery of an intact sequence facet of the RNA platform, and it is likely more therapies will be of interest to the host cell (Hoecke & Roose, 2019; Jackson et al., approved. For example, mRNA is currently being explored to 2020; Pardi et al., 2018). The sequence can code for an antigen, a express mAbs (Hoecke & Roose, 2019). These molecules would monoclonal antibody (mAb), or any other therapeutic target. The then trigger the immune response in the presence of their platform is revolutionary because modifed mRNA is more stable respective antigens. Likewise, the mRNA platform is being used for than native mRNA and is not immunogenic, thus reducing the the development of single-stranded antisense oligonucleotides immune response and improving the translation effciency. In (ASOs) (Deweerdt, 2019). ASOs bind to their complementary target addition, the formulation and encapsulation of the mRNA is critical mRNA sequence and can obstruct the splicing process, hinder 5’ to the technology since it allows the molecule to be delivered intact cap formation, mark the mRNA for destruction, and block to target cells. The mRNA is typically encapsulated in a lipid translation by the ribosome with steric obstruction. Similarly, nanoparticle, which further limits the immune response that would mRNA technology can be utilized to block translation of the mRNA trigger its destruction by the immune system. Crucially, the mRNA of interest through RNA interference (RNAi) (Deweerdt, 2019). sequence does not penetrate the cell nucleus and does not insert RNAi can occur through microRNAs and small interfering RNAs itself into the genome. Therefore, there is no genetic modifcation. (siRNAs), which can tag the mRNA for degradation and inhibit These features have allowed the rapid development of current protein translation in a manner akin to ASOs. In addition, mRNA can mRNA vaccines for the SARS-Cov-2 coronavirus pandemic. Indeed, also be employed to modulate the function of a target protein via responding to the threat of emerging coronavirus variants, mRNA the expression of RNA aptamers (Deweerdt, 2019). Table 1 vaccine manufacturers have been able to adjust their existing illustrates a sample of RNA therapies. mRNA sequences to develop new vaccine candidates. PHARMACEUTICAL / / THE RNA PLATFORM / / 2 Therapy Disease Generic/ Target Organization(s) Status Approval Type Type Brand Breast cancer BioNTech Ongoing N/A N/A Cancer Melanoma Radboud University Ongoing N/A N/A Prostate cancer Oslo University Hospital Ongoing N/A N/A HIV Erasmus Medical Centre Ongoing N/A N/A Infuenza Moderna Ongoing N/A N/A Vaccine mRNA-1273/ EMA/FDA/ COVID-19 Infectious Moderna Completed HPFB/MHRA Vaccine SARS-Cov-2 Moderna EMA/FDA/ Tozinameran/ Pfzer-BioNTech Completed HPFB/MHRA Comirnaty Akcea Therapeutics-Ionis EMA/FDA/ Inotersen/ Autoimmune Amyloidosis Completed Pharmaceuticals MHRA Tegsedi Duchenne muscular Eteplirsen/ ASO Sarepta Therapeutics Completed FDA dystrophy Exondys 51 Genetic Ionis EMA/FDA/ Nusinersen/ Spinal muscular atrophy Completed Pharmaceuticals-Biogen HPFB/MHRA Spinraza BioNTech-Johannes Cancer Lymphoblastic leukemia Ongoing N/A N/A Gutenberg University Georgia Institute of mAb Infectious RSV Technology-Emory Ongoing N/A N/A University CureVac-Acuitas Toxin Botulism Therapeutics-Tufts Ongoing N/A N/A University RNA Neuro- Pegaptanib/ AMD Astellas Pharma Completed EMA/FDA/HPFB aptamer degenerative Macugen Alnylam Patisiran/ siRNA Autoimmune Amyloidosis Completed EMA/FDA Pharmaceuticals Onpattro Table 1: Overview of the array of RNA therapeutics. Table Legend: AMD, age-related macular degeneration; ASO, antisense oligonucleotides; EMA, European Medicines Agency; FDA, Food and Drug Administration of the United States; HIV, human immunodefciency virus; HPFB, Health Products and Food Branch of Health Canada; mAB, monoclonal antibody; MHRA, Medicines and Healthcare products Regulatory Agency of the United Kingdom; mRNA, messenger ribonucleic acid; RSV, respiratory syncytial virus; SARS-Cov-2, severe acute respiratory syndrome coronavirus 2 (COVID-19); siRNA, small interfering ribonucleic acid. Source: Deweerdt, 2019; Hoecke & Roose, 2019; Jackson et al., 2020; Pardi et al., 2018. PHARMACEUTICAL / / THE RNA PLATFORM / / 3 A PRIMER ON THE mRNA MANUFACTURING PROCESS Generation of the DNA template (or transcription template) The mRNA transcript manufacturing process begins with the synthesis of the template plasmid DNA (pDNA). Molecular biologists design the DNA template which includes the genetic sequence of interest that encodes for either a candidate antigen or any therapeutic protein. Once designed and produced in small quantities, the pDNA is thereafter introduced into a bacterial host (usually Escherichia coli) for its amplifcation through cell expansion and plasmid replication. pDNA amplifcation begins in the recombinant bacterial shake fask culture and is then scaled up to a microbial fermenter. At the end of the cultivation period, the pDNA is extracted from the bacterial culture and is purifed. Typically, the harvested cells are lysed using a cell homogenizer and the pDNA is subsequently recovered from the clarifed lysate. A continuous centrifuge or a microfltration system is normally used for the clarifcation step. The pDNA is further purifed by chromatography to remove host cells and endotoxins, and flter sterilized. A diafltration step may be added to exchange the buffer for in vitro mRNA transcription. The production of pDNA can be outsourced or implemented in-house by any biopharmaceutical organization depending on the DNA requirements and scale of production. In vitro transcription of mRNA Once generated, the purifed pDNA is enzymatically linearized and added to a mixture of enzymes and nucleotides (the RNA building blocks) for the synthesis of mRNA by the enzyme RNA polymerase. This enzyme transcribes the target genetic sequence of the linearized pDNA into mRNA. After mRNA generation is complete, the template DNA is enzymatically digested with a deoxyribonuclease (DNase), and the bulk mRNA is purifed via a series of chromatography steps. The mRNA transcripts are subsequently capped on their 5’ end and then further purifed. Active research and development efforts are underway to combine the mRNA transcription and 5’-capping into one step. The capped mRNA is further purifed by chromatography, diafltered for buffer exchange, and sterile fltered for the subsequent formulation. The purity of the mRNA transcript is the key to minimizing risks of side effects and/or lack of effcacy after vaccine administration. Formulation of the mRNA transcript (drug substance) Various technologies for the formulation of mRNA vaccines exist, with microfuidic encapsulation with liposomes the customary choice. We recommend this technology, compared to others such as sonication and extrusion, since it has the advantage of consistently achieving greater control over the liposome size and favoring higher encapsulation effciencies of the drug substance. The mRNA transcript in an aqueous buffer and the lipids dissolved typically in ethanol are homogenized by microjet impingement mixing. During the mixing process, the lipids and mRNA molecules spontaneously self- assemble into loaded liposomes. The lipid types are carefully selected and buffer conditions optimized for the effcient encapsulation of the mRNA and for the correct liposome self-assembly (Buschmann et al., 2021; Kis et al., 2020). We believe, and experts agree, that this step may be one of the major bottlenecks of the manufacturing process as technologies allowing the scale up of this formulation are scarce relative to the current unprecedented demand (Lowe, 2021). The